Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications
ReviewHumans
- Design
- Review
- Subjects
- Not applicable; a hypothesis and review article
- Dose used in the study
- Not applicable; a hypothesis and review article
- Duration
- Not applicable; a hypothesis and review article
- What was measured
- Whether palmitoylethanolamide could help treat long-COVID: proposed mechanisms and possible clinical applications
What the authors reported
Palmitoylethanolamide is put forward as a possible treatment for long-COVID, particularly fatigue and myalgia, reasoning from its proposed anti-inflammatory and cytokine-modulating properties and a hypothesised role for mitochondrial dysfunction in long-COVID. No new experimental or clinical data are given.
Limits of this study
A hypothesis and narrative review, not a study; it reports no new experimental or clinical results and cannot show effect in people. The authors declare no conflicts of interest relevant to the article.
Source
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.